Date: 2014-10-28
Type of information: Financing round
Company: DCPrime (The Netherlands)
Investors: SkylineDx (The Netherlands), Van Herk Investments (The Netherlands)
Amount: undisclosed
Funding type: financing round
Planned used: The financing is designed to provide DCPrime with funding for the development of its technology platform and to take advantage of the synergies between the cancer companies. The financing arrangement provides DCPrime with funding for the coming years, and will enable DCPrime to continue the development of its DCOne™ technology platform. This platform allows development of vaccines for application in both haematological as well as solid cancers. DCPrime develops off-the-shelf dendritic cell-based vaccines for a broad range of cancer types, based on its unique, proprietary technology platform, DCOne™. DCOne-based dendritic cell vaccines, in some indications loaded with cancer antigens for targeted treatment, will be used as standardized, therapeutic products. The platform combines the power of dendritic cell-based vaccines with the advantages of allogeneic stimulation of the immune system, and the simple logistics of off-the-shelf products. DCPrime has successfully completed a Phase I/IIa study in AML and has developed a commercial scale manufacturing process for DCOne-based vaccines.
Others: * On October 28, 2014, SkylineDx, an innovative company in the field of genetic testing for blood cancers, announced a strategic investment of an undisclosed sum in the Dutch cancer vaccine company DCPrime. Van Herk Investments, an investor with a long-term investment strategy and shareholder of SkylineDx, supports the investment in DCPrime financially. The collaboration with SkylineDx will particularly strengthen the position of both companies in developing non-toxic treatment alternatives for patients with haematological cancers. SkylineDx develops and markets novel research tools and diagnostic tests using gene signatures for personalized medicine in oncology. In addition, the company continues to work with academic and industrial partners on the development and commercialization of innovative markers and tests, including companion diagnostics As the strategies of both companies will be closely aligned, DCPrime has replaced the existing supervisory board members with Dharminder Chahal, CEO of SkylineDx. In addition, Marcel Zwaal, CEO of DCPrime, has decided to resign and pursue other career opportunities. Ada Kruisbeek, founder and CSO of DCPrime, will, together with COO Sandra van Wetering, continue to develop the company’s cancer vaccine pipeline.
Therapeutic area: Cancer - Oncology
